Scrip Asia 100 - S*BIO sticks to the book on its road to market
This article was originally published in Scrip
Thanks to healthy income from licensing partners, S*BIO is in the enviable position of being able to plan carefully both its strategy for internal R&D and future financing. The attractions of Singapore have also helped S*BIO to recruit a surprisingly international workforce, Dr Jan-Anders Karlsson, the bioventure's CEO, tells Ian Haydock.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.